Edwards Lifesciences holder plans Rule 144 sale of 2,000 shares

A security holder of Edwards Lifesciences plans to sell 2,000 shares of the company’s common stock under Rule 144.

Rhea-AI Filing Summary

A security holder of Edwards Lifesciences plans to sell 2,000 shares of the company’s common stock under Rule 144. The planned sale has an aggregate market value of $168,750 and is scheduled around December 11, 2025 through broker Charles Schwab & Co., Inc. on the NYSE. The filing notes that 580,300,000 shares of Edwards Lifesciences common stock were outstanding.

The shares to be sold come from prior equity compensation awards from Edwards Lifesciences. These include restricted stock that lapsed on May 3, 2023 and May 4, 2023 in amounts of 359 and 527 shares, and RSU/PSU awards acquired on May 7, 2023 totaling 1,114 shares. The seller represents that they are not aware of any undisclosed material adverse information about the company’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Edwards Lifesciences (EW) disclose in this Rule 144 notice?

A security holder of Edwards Lifesciences filed a Rule 144 notice to sell 2,000 shares of the company’s common stock with an aggregate market value of $168,750 on the NYSE.

How many Edwards Lifesciences (EW) shares are involved in the planned Rule 144 sale?

The notice covers a planned sale of 2,000 shares of Edwards Lifesciences common stock, with an aggregate market value of $168,750.

When is the approximate sale date for the Edwards Lifesciences (EW) shares?

The approximate sale date shown in the notice is December 11, 2025 for the 2,000 Edwards Lifesciences common shares to be sold.

How were the Edwards Lifesciences (EW) shares being sold under Rule 144 originally acquired?

The shares come from equity compensation, including restricted stock lapses on May 3, 2023 (359 shares) and May 4, 2023 (527 shares), and RSU/PSU awards on May 7, 2023 totaling 1,114 shares.

How many Edwards Lifesciences (EW) shares were outstanding according to this notice?

The Rule 144 notice states that there were 580,300,000 shares of Edwards Lifesciences common stock outstanding.

Which broker will handle the Edwards Lifesciences (EW) Rule 144 sale?

The planned sale of 2,000 Edwards Lifesciences common shares is listed with broker Charles Schwab & Co., Inc. at its Westlake, Texas address.

Does the selling security holder in this Edwards Lifesciences (EW) filing make any representation about inside information?

Yes. By signing the notice, the security holder represents that they do not know of any material adverse information about Edwards Lifesciences’ current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 04:01 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001740963
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Chopra Daveen
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	2000	168750.00	580300000	12/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/03/2023	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			359	05/03/2023	Equity Compensation
Common	05/04/2023	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			527	05/04/2023	Equity Compensation
Common	05/07/2023	RSU / PSU	EDWARDS LIFESCIENCES CORPORATION			1114	05/07/2023	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	12/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daveen Chopra
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)